List of planned services moving forward:
Patient/Provider Connection
Provider Search Functionality
Appointment Scheduler
Treatment Progress Tracker
Integration with existing alternative medicine systems
CBD
“Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action“ by Roger Pertwee (2012) – This comprehensive review paper discusses the pharmacological properties and potential therapeutic applications of CBD, highlighting its diverse effects on various physiological systems.
Ketamine
“Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression“ by Carlos A. Zarate Jr., Jaskaran B. Singh, Paul J. Carlson, Nancy E. Brutsche, Rezvan Ameli, David A. Luckenbaugh, Raul R. Charney, and Dennis S. Charney (2006) – This study is often cited for its pioneering work in demonstrating the rapid antidepressant effects of ketamine in patients with treatment-resistant depression.
Psilocybin
“Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial“ by Griffiths, R. R., Johnson, M. W., et al. (2016) – This randomized double-blind trial investigated the therapeutic potential of psilocybin in reducing depression and anxiety in patients with life-threatening cancer. The study demonstrated significant and sustained decreases in symptoms following psilocybin-assisted psychotherapy.
“Navigating the FDA’s Shifting Stance on Cannabis & Psychedelics”
The shifting landscape of cannabis and psychedelics is propelled by advancing research and changing societal perspectives. Recent discussions indicate that federal legalization of psychedelics may precede that of cannabis in the United States, primarily due to the FDA’s challenge in regulating the diverse therapeutic compounds within cannabis compared to single molecules in psychedelics.
“Legalizing Marijuana, Psilocybin Mushrooms, and MDMA for Medical Use“
Understanding a nation’s drug history illuminates the shifts in policy over time. Currently, federal policies, including the DEA’s scheduling and military regulations, hinder the legalization of medical marijuana, psilocybin mushrooms, and MDMA for federal employees and veterans despite growing evidence of their therapeutic benefits.
“What Is the Current Legal Landscape of the Psychedelics Industry”
Psychedelics is an industry amid a revolution. Research, public perception, and even regulations are shifting at an incredible pace, paving the way for a nascent industry to rise in a matter of years. During such change, it can be easy to lose track of where we currently are, not where we’ll be in six months, one year, or five years.
Mission
At AltMedRX, our mission is to connect individuals struggling with mental health issues to complementary therapies while also contributing to the reduction of the opioid crisis. Improve access to complementary therapies for individuals struggling with mental health issues and contribute to reducing the opioid crisis. We envision becoming the go-to platform for connecting patients with qualified providers in alternative medicine.
Vision
Focused on constant innovation, emerging as a pioneer and recognized in the alternative medicine space, for providing superior quality solutions for our customers and partners we serve.
Why Us/Value Proposition
Our user-friendly interface currently under development, AltMedRx not only facilitates connections but also streamlines the payment process, making alternative health treatments more accessible and convenient. We recognize the growing demand for alternative therapies among individuals seeking to reduce reliance on opioids and explore holistic approaches to improving mental health. AltMedRx’s data-driven approach positions us as the premier resource in this underserved market, driving substantial growth as we continue to expand our reach and impact within the alternative health community.